Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Rafael Holdings, Inc. (RFL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: RFL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.14% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 58.27M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.92 | 52 Weeks Range 1.27 - 3.19 | Updated Date 06/29/2025 |
52 Weeks Range 1.27 - 3.19 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.92 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1633.43% |
Management Effectiveness
Return on Assets (TTM) -9.82% | Return on Equity (TTM) -26.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21022811 | Price to Sales(TTM) 79.6 |
Enterprise Value 21022811 | Price to Sales(TTM) 79.6 | ||
Enterprise Value to Revenue 28.72 | Enterprise Value to EBITDA 5.39 | Shares Outstanding 34303200 | Shares Floating 15495922 |
Shares Outstanding 34303200 | Shares Floating 15495922 | ||
Percent Insiders 54.74 | Percent Institutions 9.37 |
Upturn AI SWOT
Rafael Holdings, Inc.
Company Overview
History and Background
Rafael Holdings, Inc. is a pharmaceutical company focused on developing and commercializing therapies for cancer and immune disorders. Founded in 2017, it evolved from a holding company with diverse assets to primarily focusing on oncology. Significant milestones include acquiring Rafael Pharmaceuticals and progressing its lead drug candidate, devimistat, through clinical trials.
Core Business Areas
- Oncology Drug Development: Focused on the development and commercialization of therapies for cancer treatment, with a primary focus on their lead drug candidate, devimistat.
- Pharmaceutical Research: Engaged in preclinical and clinical research activities to discover and develop novel therapeutic agents.
Leadership and Structure
Aiman Shalabi serves as CEO. The company's organizational structure reflects its focus on pharmaceutical development, with departments dedicated to research, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Devimistat: Devimistat is Rafael Holdings' lead drug candidate, an investigational drug in clinical trials for various cancers. It is designed to target cancer cell metabolism. Specific market share data for devimistat is not yet available, as it is still in the clinical trial stage. Competitors depend on the indication but include companies developing cancer therapeutics, such as Bristol Myers Squibb (BMY), Merck (MRK), and Roche (RHHBY).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and dynamic, driven by innovation, regulatory changes, and evolving healthcare needs. The oncology market is a significant segment, characterized by high unmet needs and substantial growth potential.
Positioning
Rafael Holdings is positioned as a pharmaceutical company focused on developing novel cancer therapies. Its competitive advantage lies in its specific targeting of cancer cell metabolism with devimistat.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars annually. Rafael Holdings aims to capture a portion of this market with its innovative drug candidates, though its current positioning is still in the clinical development phase and has yet to be determined commercially.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (devimistat)
- Experienced management team
- Focus on unmet needs in oncology
Weaknesses
- Reliance on a single drug candidate
- Limited financial resources compared to larger pharmaceutical companies
- Regulatory approval risks
Opportunities
- Successful clinical trial outcomes
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Generic competition
Competitors and Market Share
Key Competitors
- Bristol Myers Squibb (BMY)
- Merck (MRK)
- Roche (RHHBY)
Competitive Landscape
Rafael Holdings faces intense competition from larger, established pharmaceutical companies with greater resources and broader product portfolios. Its success depends on the clinical and commercial success of devimistat.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the progression of devimistat through clinical trials.
Future Projections: Future growth depends on the successful development and commercialization of devimistat and other drug candidates. Analyst estimates would be based on clinical trial outcomes and regulatory timelines.
Recent Initiatives: Recent initiatives include advancing devimistat through ongoing clinical trials and exploring potential partnerships.
Summary
Rafael Holdings is a pharmaceutical company with a focus on oncology and a lead drug candidate, devimistat. Its success hinges on the positive outcomes of clinical trials and regulatory approvals. While it faces significant competition from larger pharmaceutical companies, its targeted approach to cancer cell metabolism represents a potential competitive advantage. Financial viability relies on attracting funding and the ultimate commercial success of its products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Market research reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share and financial data may be estimated or based on publicly available information. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rafael Holdings, Inc.
Exchange NYSE | Headquaters Newark, NJ, United States | ||
IPO Launch date 2018-03-26 | CEO, Founder & Executive Chairman Mr. Howard S. Jonas | ||
Sector Real Estate | Industry Real Estate Services | Full time employees 28 | Website https://www.rafaelholdings.com |
Full time employees 28 | Website https://www.rafaelholdings.com | ||
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.